Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
DHS Working Papers No. 125
Epidemiologisches Bulletin ; 12. Dezember 2016 / Nr. 49 aktuelle daten und informationen zu infektionskrankheiten und public health
Overview
Rev Panam Salud Publica 40(6), 2016
A long and healthy life for all South Africans
The END TB Strategy
Интеграция совместного оказания услуг в связи с ТБ и ВИЧ во всеобъемлющий пакет помощи для потребителей инъекционных наркотиков
This new edition and fully updated publication replaces the 2012 UCG and is being circulated free of charge to all public and private sector prescribers, pharmacists, and regulatory authorities in the country
Initiation à la Méthodologie de la recherche en Santé, Guide de Formateur
Cette Boîte à images fait partie du projet de « Promotion des services d’appui
juridique à la lutte contre le VIH/sida dans les villes de Cotonou, Porto-Novo, Abomey
Calavi et Ouidah au sud Bénin », mis en oeuvre par l’Association Béninoise de Droit
du Développement (ABDD).
La boîte... à images a été présentée sous forme d’avant-projet lors d’un atelier qui s’est
déroulé les 18 et 19 février 2016 à Ouidah. Les contributions au projet de boîte à
images des participants ont été incorporées dans la version finale.
more
UNAIDS 2016 / Meeting Report
The primary role of Benin’s Department of Pharmacy and Medicines (DPMED) is to develop and apply the national pharmaceutical policy. The main objective of this policy is to ensure the availability and accessibility of quality medicines for the population. To fulfill its mandate, DPMED aims to stre...ngthen its regulatory capacity, including the issuance of licenses to pharmaceutical establishments and the registration of pharmaceutical products. Benin’s current registration system shares core concerns that are common to most developing countries, notably the capacity to evaluate and monitor the security, efficacy, and quality of medicines and other health products. It is currently characterized by 1) poor or inadequate traceability of records or regulations (example: a product’s marketing authorization [MA] is often hard to find); 2) lack of evidence used in the regulatory decision-making process (reasons behind special import authorization, i.e., products without valid MAs); 3) inconsistent and unsecured archiving system; 4) limited human resources; and 5) an inefficient information management system
more
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0